We help oncology laboratory pharma professionals enhance patient care
Oncology professionals
We ensure NGS testing is simple to organise with timely results provided in a timely way signposting you to treatment choices that will benefit your patients.
Laboratory professionals
Our solutions always ensure that NGS testing and its clinical interpretation is delivered in a timely way for the benefit of patients.
Pharma professionals
We can gather the information needed to precisely match patients to drugs, evidencing clinical efficacy, safety and patient benefit.
Years of trust, countless tests run, genes, and trials explored
Our mission
OncoDNA’s ultimate mission is to improve all patients’ health by empowering healthcare providers, biopharma companies and researchers to deliver the promise of precision medicine. In this relentless pursuit of better care, we have been building an ecosystem of partners involved along the entire value chain – from translational research and drug development to patient treatment, monitoring and reimbursement.
Every day, our dedicated efforts focus on enhancing patient
access to Precision Medicine
OncoDNA as dedicated partner to assist KU Leuven in OncNGS consortium
With its recognised expertise in successfully commercializing decentralised testing and reporting for pan-cancer solid and hematological tumor analysis in precision oncology, OncoDNA has been selected as a dedicated partner to assist KU Leuven in implementing...
World Cancer Day: Advancing Precision Cancer Care with OncoDNA & MGI
As we celebrate World Cancer Day, we’re spotlighting the transformative impact of genomics in precision medicine for oncology. The theme of World Cancer Day 2025 is “United by Uniquel”, today in the latest episode of...
Analysis of comprehensive genomic profiling of solid tumors with a novel assay for broad analysis in clinical diagnostics
Abstract Somatic multigene analysis by next-generation sequencing (NGS) is routinely integrated in medical oncology for clinical decision-making. However, with the fast-growing number of recommended and required genes as well as pan-cancer biomarkers, small panels have...
OncoDNA at Medlab Middle East 2025 – Meet us in Dubai!
From February 3 to 6, 2025, OncoDNA will be attending Medlab Middle East at the Dubai World Trade Centre, one of the main events for the medical laboratory industry in the region. This event is...
Festival Of Genomics January 2025
We help you navigate a complex genomics ecosytem OncoDNA understands the complexities of the personalized medicine ecosystem and leverages over 10 years of expertise in genomic profiling to guide laboratories and oncologists in their use...
In this episode, Pr. Daniela Cesselli (University of Udine) discusses the strategic needs that drove the adoption of a CGP panel and the reasons behind choosing the 𝗢𝗻𝗰𝗼𝗗𝗘𝗘𝗣® 𝗞𝗶𝘁 solution. Was it to ensure timely...
Webinar : Comprehensive Genomic Profiling: What’s the Business Case? Hear the experience of an existing OncoDEEP® Kit customer
Is Comprehensive Genomic Profiling right for your lab? Download the webinar replay: Comprehensive Genomic Profiling: What’s the Business Case? Hear the experience of an existing OncoDEEP® Kit customer Wednesday, December 11, 20244:00 PM CET By...
MGI and OncoDNA join forces to offer laboratories a streamlined NGS workflow for implementing Comprehensive Genomic Profiling (CGP) OncoDEEP® Kit in clinical practice
Gosselies – Belgium, October 29, 2024 MGI (MGI Tech Co., Ltd. or its subsidiaries, together referred to MGI), a company committed to building core tools and technologies that drive innovation in life science, today announced...
The NHS South East Genomic Medicine Service transitions to the OncoDEEP Kit a Solid Tumour Panel that can transform oncology patients’ lives as a result of timely comprehensive genomic testing.
The NHS South East Genomic Medicine Service serves approximately 15.4% of the population of England and seeks to improve patient outcomes through care pathway development enabling timely and equitable access to genomic testing and genomically...
